Sign inJoin waitlistJoin the waitlist

Biljana Horn

Professor & Director, Pediatric Bone Marrow Transplant · University of Florida College of Medicine

Credentials: · ·

History

University of Florida College of Medicine
Present

National Cancer Institute
1986–1987
Case Western Reserve University
1983–1986
UNIV OF ZAGREB, SPLIT BRANCH, SCH OF MED, SPLIT, CROATIA
1979–1983

Research

Allogeneic human mesenchymal stem cell therapy (remestemcel-L, Prochymal) as a rescue agent for severe refractory acute graft-versus-host disease in pediatric patients
Biology of Blood and Marrow Transplantation · 2014 · 180 citations
Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A…
Transplantation and Cellular Therapy · 2021 · 172 citations
A Phase 3, Single-Arm, Prospective Study of Remestemcel-L, Ex Vivo Culture-Expanded Adult Human Mesenchymal Stromal Cells for the Treatment of Pediatric Patients Who Failed to…
Biology of Blood and Marrow Transplantation · 2020 · 161 citations

Morton Cowan
30 papers
Christopher Dvorak
21 papers
DT
Dirk Thye
6 papers
JW
Justin Wahlstrom
6 papers
GH
Gregory Hale
5 papers
BS
Bipin Savani
4 papers
DC
Deepakbabu Chellapandian
4 papers
EN
Eneida Nemecek
4 papers
Joanne Kurtzberg
4 papers
JF
John Fort
4 papers
Katherine Matthay
4 papers
Michael Joyce
4 papers

Clinical trials

Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
Principal investigator · Completed · Phase 1, Phase 2
University of Florida
2018–2023
A Study of Withdrawal of Immunosuppression and Donor Lymphocyte Infusions Following Allogeneic Transplant for Pediatric Hematologic Malignancies
Principal investigator · Completed · Phase 2
University of California, San Francisco
2009–2015
Donor Stem Cell Transplant Followed By Donor White Blood Cell Infusions in Treating Young Patients With Hematologic Cancer
Study chair · Terminated
University of California, San Francisco
2003–2007
The EndRAD Trial: Eliminating Total Body Irradiation (TBI) for NGS-MRD Negative Children, Adolescents, and Young Adults With B-ALL
Site PI · Recruiting · Phase 2
Pediatric Transplantation & Cellular Therapy Consortium
2018–2026